Sarcoma, Clear Cell clinical trials
The registry lists 27 studies for Sarcoma, Clear Cell across more than 10 countries. 9 are recruiting or about to start. 8 of them are mainly about Sarcoma, Clear Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26.
Get an email when these change. Save the Sarcoma, Clear Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (3) · St. Jude Children's Research Hospital (2) · Emory University (2) · Seattle Children's Hospital (2) · Salarius Pharmaceuticals, LLC (2) · Dana-Farber Cancer Institute (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · University of Florida (1)
What is being tested here
Drugs under test in Sarcoma, Clear Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Seclidemstat | 1 | 0 | 2 |
| Pazopanib | 1 | 1 | 2 |
| Tebentafusp | 1 | 0 | 1 |
| Selinexor | 1 | 0 | 1 |
| Zoledronic Acid | 1 | 0 | 1 |
| Vebreltinib | 1 | 0 | 1 |
| Cabozantinib | 0 | 0 | 1 |
| Atezolizumab | 0 | 0 | 1 |
| Doxorubicin | 0 | 1 | 1 |
| Ifosfamide | 0 | 1 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Mar 2027B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) · St. Jude Children's Research Hospital
Who these studies take
Of the 7 Sarcoma, Clear Cell studies recruiting now, 4 (57%) set no upper age limit and 3 (43%) stop at 75 or younger. 4 (57%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (43%) | 3 (43%) |
| 18 | 7 (100%) | 7 (100%) |
| 30 | 5 (71%) | 5 (71%) |
| 40 | 4 (57%) | 4 (57%) |
| 50 | 4 (57%) | 4 (57%) |
| 65 | 4 (57%) | 4 (57%) |
| 75 | 4 (57%) | 4 (57%) |
| 85 | 4 (57%) | 4 (57%) |
Across all 27 studies, recruiting or not: 33% stop at 75 or younger and 33% at 65; 78% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 27 of 27. search them.
- A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell SarcomaRecruitingNCT06942442Phase 22 countries
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/21 country
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsRecruitingNCT06625190Phase 1/21 country
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)RecruitingNCT04897321Phase 11 country
- Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma GroupRecruitingNCT03967834Not applicable1 country
- Vebreltinib for Advanced or Metastatic CCSRecruitingNCT07153887Phase 21 country
- Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue SarcomaNot yet recruitingNCT06526897Not applicable
- A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Enrolling by invitationNCT05266196Phase 1/21 country
- Clinical Application of 18F-PFPN PET Imaging in Diagnosis and Staging of Clear Cell Sarcoma of Soft TissueRecruitingNCT05963035Not applicable1 country
- EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT03618381Phase 11 country
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 21 country
- Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced ChondrosarcomaActive, not recruitingNCT04458922Phase 22 countries
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/33 countries
- B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 11 country
- Molecular-Guided Therapy for Childhood CancerCompletedNCT02162732Not applicable2 countries
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedNCT03277924Phase 1/23 countries
- QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell SarcomaTerminatedNCT03132155Phase 21 country
- Study on TSR-042 in Advanced Clear Cell SarcomaTerminatedNCT04274023Phase 21 country
- CREATE: Cross-tumoral Phase 2 With CrizotinibCompletedNCT01524926Phase 210 countries
- Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related SarcomasActive, not recruitingNCT03600649Phase 11 country
- To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissueCompletedNCT04593758Phase 1/21 country
- Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV MelanomaCompletedNCT00258687Phase 11 country
- Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue SarcomasStatus unknownNCT03989596Phase 21 country
- Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 21 country
- Aflac ST0901 CHOANOME - Sirolimus in Solid TumorsCompletedNCT01331135Phase 11 country
- Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS TumorsCompletedNCT02390843Phase 11 country
- Phase 2 Study in Patients With MiT TumorsCompletedNCT00557609Phase 23 countries